NCT02370706 - Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2015

Primary Completion Date

November 9, 2020

Study Completion Date

November 9, 2020

Conditions

Myelofibrosis

Interventions

DRUG

PIM447

pan-pim inhibitor

DRUG

Ruxolitinib

JAK1/JAK2 inhibitor

DRUG

LEE011

CDK4/6 inhibitor

Trial Locations (9)

Novartis Investigative Site, VIC

Novartis Investigative Site, Florence

Novartis Investigative Site, Mainz

Novartis Investigative Site, Ulm

Novartis Investigative Site, Villejuif

Novartis Investigative Site, Singapore

Novartis Investigative Site, Toronto

Novartis Investigative Site, Rotterdam

Novartis Investigative Site, London